GLP-1 Drugs and a Rare Neurological Disorder: What a New Study Found
A recent study has drawn attention to a rare but potentially serious neurological condition reported in some people taking GLP-1 receptor agonist medications. Researchers identified 15 reported cases of Wernicke encephalopathy among patients who had been treated with GLP-1 drugs.
The findings are noteworthy because Wernicke encephalopathy can cause serious neurological problems if it is not recognized and treated promptly. At the same time, the study does not establish that GLP-1 medications caused the condition in the patients involved.
The research was published in the journal Clinical Nutrition and examined reports involving GLP-1 receptor agonists, a class of medications widely used in the treatment of type 2 diabetes and, for some products, chronic weight management.
What did the researchers find?
Researchers identified 15 cases of Wernicke encephalopathy in people receiving GLP-1 receptor agonists. Fourteen of those cases were reported during 2023 and 2024.
Thirteen cases came from the U.S. Food and Drug Administration's Adverse Event Reporting System. Another case was identified through published medical literature, while a further case came from the researchers' own medical center.
Semaglutide was involved in eight cases, while tirzepatide was involved in six. Semaglutide is the active ingredient in medications including Ozempic and Wegovy. Tirzepatide is marketed under brand names including Mounjaro and Zepbound.
The researchers described Wernicke encephalopathy as a potentially rare but serious adverse event and said greater awareness may be useful when patients taking these medications develop prolonged vomiting, substantial weight loss, or inadequate nutritional intake.
What is Wernicke encephalopathy?
Wernicke encephalopathy is a neurological disorder associated with a deficiency of thiamine, also known as vitamin B1.
Thiamine plays an important role in the body's energy metabolism and helps brain cells function properly. When the body does not receive enough thiamine, neurological problems can develop.
Commonly recognized symptoms include confusion or changes in mental status, problems with balance and coordination, and abnormal eye movements.
However, not every patient develops the complete set of symptoms. This can make recognition more difficult in some cases.
The condition is considered a medical emergency because delayed treatment can increase the risk of permanent neurological damage.
The National Library of Medicine notes that suspected Wernicke encephalopathy requires prompt treatment, generally involving thiamine administration. The specific treatment approach depends on the patient's circumstances and should be determined by qualified medical professionals.
Why could nutrition matter for some GLP-1 patients?
GLP-1 medications can affect appetite and food intake. Gastrointestinal side effects, including nausea and vomiting, are also recognized with these medications.
For most patients, these effects do not necessarily lead to a severe nutritional deficiency. However, researchers suggested that prolonged vomiting, reduced food consumption, significant weight loss, or malnutrition could potentially contribute to thiamine depletion in susceptible individuals.
In the study, 13 of the 15 patients had at least one gastrointestinal or nutritional issue. Reported problems included vomiting, appetite loss, malnutrition, and weight loss.
This finding provides an important area for further research, but it should not be interpreted as proof that GLP-1 treatment caused Wernicke encephalopathy.
Nutritional deficiencies can have multiple causes, and Wernicke encephalopathy itself is not exclusive to people taking GLP-1 medications.
What symptoms should patients know about?
The symptoms associated with Wernicke encephalopathy can overlap with other medical conditions.
Potential warning signs include significant confusion or changes in mental state, difficulty walking or maintaining balance, and unusual eye movements.
Persistent vomiting and an inability to maintain adequate food or fluid intake may also warrant medical attention, particularly if accompanied by neurological symptoms.
Patients taking GLP-1 medications who experience severe or prolonged gastrointestinal symptoms, substantial unexplained weight loss, or symptoms affecting their neurological function should contact a health care professional.
Because Wernicke encephalopathy can progress quickly, suspected cases require urgent medical assessment.
What does the study actually prove?
This is an important distinction.
The researchers found reports of Wernicke encephalopathy among people who had received GLP-1 medications. They also found that such reports occurred more frequently with GLP-1 drugs than with other medications in the FDA database.
However, adverse-event reporting databases cannot establish that a medication caused a particular illness.
Such databases are useful for detecting possible safety signals, but reports can contain incomplete information. They can also be affected by reporting patterns, increased awareness of a particular condition, and greater attention from patients or health care professionals.
The number of reported cases also does not establish how frequently Wernicke encephalopathy occurs among people using GLP-1 medications.
In other words, the study identifies a possible safety signal that deserves further investigation. It does not demonstrate that GLP-1 medications directly cause Wernicke encephalopathy.
Not every patient had the classic symptoms
The researchers also highlighted the varied presentation of the reported cases.
Only two of the 15 patients had the traditional combination of altered mental status, impaired coordination, and abnormal eye movements.
Eleven patients experienced at least one of those symptoms.
This variation matters because clinicians may not always see the complete classic presentation. Recognizing neurological symptoms in the context of severe nutritional problems may therefore be important when evaluating patients.
Among the 11 patients for whom follow-up information was available, seven experienced long-term neurological complications.
The finding underscores why timely recognition and treatment are important when Wernicke encephalopathy is suspected.
Wernicke encephalopathy has many causes
It is also important to remember that Wernicke encephalopathy is not a condition unique to GLP-1 medications.
The disorder is traditionally associated with chronic alcohol misuse, but it can also occur in people experiencing severe malnutrition or prolonged vomiting.
Other recognized risk factors include bariatric surgery, severe pregnancy-related vomiting, certain illnesses, and circumstances that interfere with nutrition or thiamine absorption.
Consequently, doctors evaluating a patient with suspected Wernicke encephalopathy need to consider the individual's broader medical and nutritional history rather than focusing on one medication alone.
What should patients do?
People prescribed GLP-1 medications should not stop or change their treatment based solely on this study.
Instead, patients should discuss concerning symptoms with their health care provider. Particular attention may be appropriate if someone develops persistent vomiting, very poor nutritional intake, substantial weight loss, confusion, difficulty walking, balance problems, or abnormal eye movements.
Health professionals can assess whether symptoms could be related to medication effects, nutritional deficiencies, another medical condition, or a combination of factors.
The study's findings serve primarily as a reminder that severe nutritional problems can have neurological consequences and that unusual symptoms deserve prompt medical evaluation.
Conclusion
The new research identifies 15 reported cases of Wernicke encephalopathy among people taking GLP-1 receptor agonists. Most of the reported patients also experienced gastrointestinal or nutritional problems, including vomiting, appetite loss, malnutrition, or significant weight loss.
The findings raise a potential safety signal that researchers believe deserves additional attention. However, the study does not establish that GLP-1 medications caused the neurological disorder, nor does it determine how frequently Wernicke encephalopathy occurs among people taking these drugs.
For patients, the practical message is to pay attention to persistent gastrointestinal symptoms and signs of neurological changes and to seek medical advice when they occur. Suspected Wernicke encephalopathy requires urgent medical evaluation because early treatment can help reduce the risk of lasting neurological damage.
Sources
- Clinical Nutrition study on Wernicke encephalopathy and GLP-1 receptor agonists
- National Library of Medicine, Wernicke Encephalopathy
Disclaimer
This article is for general informational purposes only and is not medical advice. It does not diagnose, treat, or prevent any medical condition. Patients should consult a qualified health care professional about symptoms, nutritional concerns, medication side effects, or changes to prescribed treatment. Do not stop or discontinue a prescribed medication without discussing it with your health care provider.